Anterior Segment
Conference Roundup

Study confirms fluocinolone acetonide insert safe, effective for NIU-PS

Posted on

Three-year results from a confirmatory trial of a 36-month 0.18-mg fluocinolone acetonide intravitreal insert (Fai/Yutiq, EyePoint Pharmaceuticals) for noninfectious uveitis affecting the posterior segment (NIU-PS) confirmed the safety and effective control on NIU-PS and long-term continuous inflammation control with the insert without unanticipated side effects. In addition, the IOP elevation and cataracts were manageable, according to an on-demand presentation during 2020 AAO Virtual.

Uveitis is often chronic and requires long-term therapy to prevent secondary vision-threatening complications. For the study participants with recurrent NIU-PS were randomized to treatment with FAi or sham injection. Uveitis recurrence was the primary efficacy endpoint. One hundred and fifty-three eyes (101 FAi and 52 sham) were enrolled at 15 sites in India. During the study, uveitis recurred in 46.5% of FAi-treated eyes. Recurrence was more frequent in sham-treated eyes (75.0%), and the median recurrence time was shorter at 190.5 days. Visual acuity was stabilized or improved in approximately 90% of eyes in each group. At 36 months, macular edema was resolved in 76% of FAi-treated eyes (25/33) and 54% of sham-treated eyes (7/13). Seventy-four percent of FAi- and 73% of sham-treated eyes required IOP-lowering drops, while 2% of eyes in the FAi group and no eyes in the sham group required IOP-lowering surgery. Cataract extraction and IOL implantation was performed on 71% and 27% of phakic study eyes in the FAi and sham groups.

Jaffe GJ, et al. FAi Insert treatment for noninfectious posterior uveitis: three-year results of a confirmatory trial. Presented at: AAO 2020 Virtual [Session: OnDemand PA063.01].

Related Articles
How do patients use social media after cataract surgery?
Jul 29, 2021
Cataract surgery reduces average number ocular hypotensive medications
Jul 22, 2021
American Academy of Ophthalmology and ASCRS Urge Aetna to Reverse Disruptive New Policy on Cataract Surgery
Jul 05, 2021